(Q37773266)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

review article

1 reference

title

Dendritic cell preparation for immunotherapeutic interventions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Jean-Francois Fonteneau

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Marc Grégoire

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

1 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

289-302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

Progress in human tumour immunology and immunotherapy

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

The interactions of dendritic cells with antigen-specific, regulatory T cells that suppress autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Development of dendritic-cell lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Origin, maturation and antigen presenting function of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Tolerance, danger, and the extended family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Toll-like receptors and dendritic cells: for whom the bug tolls

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

The heat-shock protein receptors: some answers and more questions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Danger signals: a time and space continuum.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Tolerogenic dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

The diversity of immunological synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Cooperation between CD4+ and CD8+ T cells: when, where, and how.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Making sense of mass destruction: quantitating MHC class I antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Proteasome and peptidase function in MHC-class-I-mediated antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Immunobiology of interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cell-mediated T cell polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic-cell-based therapeutic vaccination against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Immunotherapy with dendritic cells for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cell vaccine strategies for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cell immunotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cell vaccines in acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cell immunotherapy for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Culture medium and protein supplementation in the generation and maturation of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Regulation of T cell immunity by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Helper activity is required for the in vivo generation of cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cells as vectors for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Review: cancer immunotherapy by exosome-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cell derived-exosomes: biology and clinical implementations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

The induction of tolerance by dendritic cells that have captured apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Natural killer cell-directed therapies: moving from unexpected results to successful strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Taming cancer by inducing immunity via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Dendritic cell vaccination and immune monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.289

21 January 2018

Identifiers

DOI

10.2217/1750743X.1.2.289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635946%20AND%20SRC:MED&resulttype=core&format=json

release_a3xxrq5cdnc7rcfab6wg265zkm

7 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a3xxrq5cdnc7rcfab6wg265zkm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference